

## ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate

**STOCKHOLM – July 6, 2021** – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in Columbus, OH, and with Tufts Medical Center (Tufts MC), Boston, MA.

Principal investigators for the study are Professor Anil Parwani, M.D., Ph.D., M.B.A at OSUCCC – James and Ming Zhou, MD, PhD, Chair and Pathologist-in-Chief at Tufts MC. The study will evaluate how INIFY Prostate can improve the performance of resident diagnosis when reviewing prostate biopsy samples. Ground truth will be provided by the two principal investigators, world-renowned sub-specialists within prostate cancer.

INIFY is a powerful AI-based software that precisely outlines suspected cancerous areas in prostate biopsies, with unique, detailed pixel-level focus. Based on a patented annotation method used in training of the algorithms – MasterAnnotation – INIFY pre-sorts slides in a worst-first order, and comes with a user-friendly viewer designed for handling prostate biopsies.

*“As president of the Digital Pathology Association and one of few sites in the US being fully digitalized, I’m eager to explore how the use of AI-based decision support tools can support prostate diagnosis, and potentially improve workflow,”* says Anil Parwani, Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at OSUCCC – James.

*“At Tufts Medical Center, we are in the process of digitalizing pathology,”* says Dr. Zhou, Chair and Pathologist-in-Chief at Tufts MC. *“Our department certainly would benefit from a tool to support high quality diagnosis and speed up this transition.”*

*“We are very excited and proud to have the opportunity to cooperate with two of the most respected pathologists within the society, and their clinics, for driving the digitalization process,”* says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.

**The Ohio State University** Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved



Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. To learn more, visit [cancer.osu.edu](http://cancer.osu.edu).

**Tufts Medical Center** is an exceptional, not-for-profit, 415 bed academic medical center that is home to both a full-service hospital for adults and Tufts Children's Hospital. Tufts MC's renowned research program ranks among the top 10 percent of independent hospitals to receive federal research funding. The Medical Center is the principle teaching hospital for Tufts University School of Medicine. The Department of Pathology and Laboratory Medicine includes more than 200 dedicated pathologists, medical technologists, medical technicians, phlebotomists and administrative staff who provide comprehensive diagnostic testing services in a wide variety of areas within anatomic and clinical pathology. The faculty members are engaged in cutting edge research that aims to translate bench research to bedside patient care.

###

### **About ContextVision**

ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools, and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

For further information, please contact ContextVision's CEO, Fredrik Palm, at +46 76 870 25 43 or visit [www.contextvision.com](http://www.contextvision.com)